Search clinical trials for: Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors

Total 4689 results

Anhui Provincial Hospital

Recruiting

Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer

Esophageal Squamous Cell Carcinoma

China
Hunan Province Tumor Hospital

Completed

ICI-combined Strategies Presented With Promising Efficacy in NSCLC Patients

Non Small Cell Lung Cancer

China
Xiangya Hospital of Central South University
Wu Jieping Medical Foundation

Recruiting

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Non-small Cell Lung Cancer Metastatic | Brain Metastases

China
Qianfoshan Hospital

Recruiting

Low-dose Radiotherapy Combined With Conventional Fractionated Radiotherapy in Lung Cancer After Immunotherapy Resistance (FL002)

Cancer Patients

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Chuangzhen Chen

Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors (ILDRV1)

Radiotherapy | Immune Checkpoint Blockade | Metastatic Extracranial Malignant Solid Neoplasm | Resistance to Immunotherapy

China
Yong Zhang,MD

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Uterine Cervical Neoplasms

China
Ospedale Maggiore Di Trieste

Unknown

Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma (ICI-RT-1)

Hodgkin Lymphoma | Radiotherapy | Immune Checkpoint Inhibitor

Italy
Texas Tech University Health Sciences Center

Not yet recruiting

Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers (LOGIC)

Triple Negative Breast Cancer
Sichuan University

Not yet recruiting

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Solid Tumor
Shanghai Chest Hospital

Not yet recruiting

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (RICE)

Chemotherapy | Immunotherapy | Concurrent Chemoradiotherapy | Esophageal Squamous Cell Carcinomas
Xinqiao Hospital of Chongqing

Recruiting

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Lung Cancer | Radiotherapy | Immune Checkpoint Inhibitor

China
Henan Cancer Hospital

Active, not recruiting

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

HER2 Positive Metastatic Breast Cancer

China
XIANG YANQUN

Active, not recruiting

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Chemotherapy Effect | Metastatic Nasopharyngeal Carcinoma

China
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

China
University Hospital Freiburg

Unknown

Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT) (α-RT)

Prostate Carcinoma

Germany
Sun Yat-sen University

Active, not recruiting

Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Stage III Non-small-cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

Radiotherapy | Rectal Neoplasms Malignant

China
Xiangdong Cheng

Recruiting

Nivolumab Combined With SOX Used in the Perioperative Treatment

Gastric Cancer | Immune Suppression

China
Shanghai Chest Hospital
Bristol-Myers Squibb

Completed

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

NSCLC Stage IV | Checkpoint Inhibitor

China
Jiangsu Cancer Institute & Hospital

Recruiting

High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM (HaRyPOT)

Colorectal Liver Metastases

China
Xuzhou Medical University

Recruiting

A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Lung Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Hepatocellular Carcinoma | Radiotherapy | Pembrolizumab | Tumor Thrombosis

China
Pancreatic Cancer Action Network

Active, not recruiting

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
China Medical University Hospital

Unknown

Combined Radiotherapy and Sorafenib in Patients With Hepatoma

Hepatocellular Carcinoma

Taiwan
University Medical Centre Maribor
Institute of Oncology Ljubljana; The University Clinic of Pulmonary and Allergic...

Recruiting

Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (PRIMM)

Carcinoma, Non-Small-Cell Lung | Non Small Cell Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma

Slovenia
Luo Cong

Completed

The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer

China
Hunan Cancer Hospital

Completed

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
Hospital Universitario Araba
Hospital Donostia; Hospital de Basurto; Complejo Hospitalario de Navarra; Hospital...

Recruiting

Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC) (AUTENTIC)

Cancer | Metastatic Cancer | Solid Organ Cancer

Spain
The Affiliated Hospital of Qingdao University

Completed

The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

NSCLC | Angiogenesis | Immunotherapy

China
Sichuan University

Recruiting

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NSCLC | PD-1 Inhibitor | Stereotactic Body Radiotherapy | Low Dose Radiotherapy

China
Sun Yat-sen University

Recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | Immune Checkpoint Inhibitor

China
ImmuneSensor Therapeutics Inc.

Completed

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Solid Tumor, Adult

United States
Pengyuan Liu
Zhejiang Hospital

Completed

Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours (HEAIS001)

Gastrointestinal Tumor

China
Simcere Pharmaceutical Co., Ltd
Daping Hospital and the Research Institute of Surgery of the Third Military...

Unknown

Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
University Hospital, Ghent
Jules Bordet Institute; AZ Sint-Lucas Gent; GZA Ziekenhuizen Campus Sint-Augustinus and other collaborators

Completed

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors (CHEERS)

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma

Belgium
Yuankai Shi

Completed

Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China

Head and Neck Squamous Cell Carcinoma

China
Clinica Universidad de Navarra, Universidad de...
Highlight Therapeutics

Recruiting

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC (Noelia)

Non-Small Cell Lung Cancer Metastatic

Spain
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Capecitabine | Radiotherapy | PD-1 Inhibitor

China
VastBiome

Recruiting

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors (PARADIGM)

Renal Cell Carcinoma | Non-Small-Cell Lung Carcinoma | Malignant Melanoma | Triple-Negative Breast Cancer

United States
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Safety Issues | Efficacy, Self

Mexico
Shanghai First Maternity and Infant Hospital

Unknown

Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer (ECCT)

Endometrial Cancer Stage I
Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction (CHIMeRA)

Autoimmune Diseases | Endocrine System Diseases | Cancer | Arthritis | Myositis | Neuropathy | Cardiac Disease | Ophthalmopathy

France
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Recruiting

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

NSCLC | Lung Diseases, Interstitial | Immunotherapy

Belgium
Peking University Cancer Hospital & Institute

Not yet recruiting

Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC

Non Small Cell Lung Cancer

China
Flinders University
Flinders Medical Centre; Lyell McEwin Hospital

Recruiting

Assessment of Myocardial Injury in Patients Treated With Immune Checkpoint Inhibitors (MIICI)

Myocardial Injury | Myocarditis | Cardiotoxicity | Immune Checkpoint Inhibitors

Australia
XIANG YANQUN

Recruiting

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | T2-3N0 or T1-2N1 | EBV-DNA≤4000 Copy/ml

China
Qingdao Central Hospital

Recruiting

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Metastatic Esophageal Squamous Cell Carcinoma

China
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Recruiting

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

Immunotherapy | Pneumonitis, Interstitial | Immune-related Adverse Events

Belgium
Erasmus Medical Center

Recruiting

Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study (SANO-3)

Esophageal Cancer

Netherlands

Search clinical trials for: Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations